Clene raises $4M in direct offering to fund operations into 2027

Clene Inc. (NASDAQ: CLNN), a clinical-stage biotechnology company, priced a registered direct offering of 1,219,513 shares at $3.28 per share, raising $4 million in gross proceeds, according to a company press release dated Sept. 15, 2026.

The offering was made to existing shareholders, including insiders. Participants include Chairman of the Board David Matlin, founding investor Kensington Capital Holdings, and the company's chief executive officer. The transaction was conducted without a placement agent, underwriter, broker, or dealer.

The offering was expected to close on Sept. 17, 2026. Clene said the proceeds, combined with existing cash, are expected to fund operations through mid-first quarter 2027.

The company said it intends to use the funds for general corporate purposes, including regulatory dialogue and preparation of filings for its drug candidate CNM-Au8, expanded access protocols, potential future commercialization efforts, and manufacturing expansion.

The offering was made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission under the Securities Act of 1933.

You May Also Be Interested In

• Forward Industries plans $25M stock offering to buy Solana
• Flywire adds ex-GitLab CTO Sabrina Farmer to its board
• Biomea Fusion launches public offering of common stock and warrants